// App-Quantinova.ai

e15602 : Population pharmacokinetics of CAP7.1 and the effect on total target lesion size in adult patients with biliary tract cancer.

Researchers

Presenter

  • Matthias Machacek

Principal Investigators

  • Ulrich-Frank Pape

  • Ulrich Keilholz

  • Marianne Sinn

  • Stefan Kasper

  • Johannes Meiler

  • Arndt Vogel

  • Lothar Mueller

  • Karel Caca

  • Jan Kuhlmann

  • Oswald Burkhard

  • Victor Rodriguez Laval

  • Glyn Steventon

  • Nalan Utku

  • Holger Jansen

Medical Centers

  • LYO-X GmbH, Allschwil, Switzerland

  • Department of Internal Medicine, Charite-Universitatsmedizin, Berlin, Germany

  • Department for Hemato-Oncology, Comprehensive Cancer Center, Charite-University Medicine, Berlin, Germany

  • Medizinischen Klinik m.S. Hepatologie und Gastroenterologie, Berlin, Georgia

  • Department of Surgery, Westgerman Cancer Center, University Hospital Essen, Essen, Germany

  • Hannover Medical School, Hannover, Germany

  • Onkologie Praxis, Leer, Germany

  • Klinikum Ludwigsburg, Ludwigsburg, Germany

  • Department of Medicine II, University Hospital Freiburg, Freiburg, Germany

  • Onkologie Praxis, Leer, Germany

  • Instutut fur Radiologie, Berlin, Germany

  • University of Surrey, Guildford, United Kingdom

  • CellAct, Dortmund, Germany

  • CellAct Pharma GmbH, Dortmund, Germany

Locations

  • Germany

  • Switzerland

  • Georgia

  • United Kingdom

Companies

  • LYO-X GmbH

  • CellAct Pharma GmbH

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Advanced biliary tract carcinoma

Biomarkers

  • N/A

Drug/Treatment

  • Etoposide

  • Etoposide phosphate

  • Etoposide toniribate

Outcome

  • Unknown

Study Design

  • Randomized

  • Pharmacokinetics

  • Open Label

  • Multicenteric

  • Dose Escalation

Phase

  • II

Study Id's

  • NCT02094560

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved